Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.


The increasing prevalence of drug-resistant gram-positive cocci, such as methicillin-resistant Staphylococcus aureus, has underscored the need for new agents for the treatment of this type of infection. Dalbavancin, a new lipoglycopeptide, has the desirable characteristics of increased in vitro activity, compared with vancomycin, for most gram-positive… (More)
DOI: 10.1086/526772


3 Figures and Tables

Slides referencing similar topics